Microbial biofactories for the production of natural compounds applicable in medicine, cosmetics and food
A European project has developed a new technology based on microbial communities as a sustainable alternative for the production of natural products.
Researchers from the Consejo Superior de Investigaciones Científicas (CSIC) participate in the SynBio4Flav project, which develops a technology for the production of flavonoids and other highly complex natural substances using microbial communities as biofactories. This novel technology can become a sustainable alternative to the traditional production of these substances from plant extracts, which is ecologically inefficient and with very low yields. Flavonoids are very valuable compounds due to their multiple applications in medicine, cosmetics and food.

Researchers have developed a novel flavonoid production technology.
CNB-CSIC
The project, led by National Center for Biotechnology (CNB-CSIC) researcher Juan Nogales, develops a production technique that allows a more efficient use of available resources by using microbial communities capable of replicating plant flavonoid synthesis processes. "The pioneering approach of SynBio4Flav has potential to be applied to the sustainable production of other complex organic compounds," says Nogales.
The researchers take advantage of the great biosynthetic potential of microbes and of their ability to co-exist in synergistic communities. "Instead of optimizing a single microbial species to produce flavonoids, the different stages of the production process are distributed among several species. This is a method based on the functional complementarity of microbial communities, where the production of one species serves as a resource for another," explains the researcher.
The ultimate goal of the project is to develop local microbial factories with a high capacity to transform urban and agricultural organic waste into value-added natural products. "The potential economic and environmental benefits are numerous, as this will allow compounds that are currently expensive and scarce to become affordable, as well as contributing to the conservation of natural resources," says Nogales.
SynBio4Flav is a project funded by the European Union's Horizon 2020 Research and Innovation Program and involves the participation of research organizations, academic institutions, SMEs and large leading companies from Spain, Germany, Sweden, Poland, France, Italy and Austria.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in Spanish can be found here.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Beetroot peptide as potential drug candidate for treating neurodegenerative and inflammatory diseases - Peptide is able to inhibit a particular enzyme that is responsible for the breakdown of messenger molecules in the body
RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks
Generex Biotechnology to begin human trial of avian influenza vaccine
Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian
Bio-molekula new distributor for Carlo Erba Reagents in Germany
Erasing a genetic mutation

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy - Growth through investments in the “Big 3”

A new, highly sensitive chemical sensor uses protein nanowires - UMass Amherst team introduces high-performing 'green' electronic sensor

Beta cells from stem cells: Potential for cell replacement therapy - Quality control with CD177 can help save lots of time, efforts and money
Mutation of BAP1 gene passed down over centuries
GM chickens that don't transmit bird flu developed - Breakthrough could prevent future bird flu epidemics
